HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Inclusion Criteria:

   - Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or
   urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is
   the predominant cell type.

   - Locally advanced unresectable or metastatic stage disease

   - Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned
   slides, see laboratory manual for details) available for HER2 testing.

   - At least 1 prior line of systemic therapy for locally advanced unresectable or
   metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing
   chemotherapy.

   - Initiation of anticancer therapy for UC after prior progression on platinum-based
   therapy with or without maintenance avelumab between 01 January 2019 and 12 months
   before the end of data collection

   - Radiographically documented and measurable disease progression immediately before
   index date

Exclusion Criteria:

   - Any concurrent malignant neoplasm requiring systemic therapy during the study window

   - Enrollment in a therapeutic clinical trial and received non-standard of care treatment
   during index line of therapy